76 results
Page 3 of 4
8-K
EX-99.1
tt0tw54p3zisf5owj
1 Aug 22
Candel Therapeutics Appoints Three New Members to its Board of Directors
6:09am
8-K
EX-99.1
5hveff7
26 May 22
Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer
5:36pm
8-K
EX-99.1
8jquyps2hx371p
12 May 22
Candel Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
8:15am
10-K
5ag95dc
29 Mar 22
Annual report
8:46am
10-K
EX-10.12
sc1vu2p4rzjmyyp8
29 Mar 22
Annual report
8:46am
10-K
EX-10.11
ay6ehn3gecjiha0
29 Mar 22
Annual report
8:46am
8-K
EX-99.1
e4zwx
29 Mar 22
Candel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Highlights
8:32am
8-K
EX-99.1
a51j8f gm
1 Mar 22
Candel Therapeutics Announces $25 Million Non-dilutive Debt Financing Agreement with Silicon Valley Bank
8:09am
8-K
EX-99.1
3seoz 3eqlsyh8b4q1b
9 Feb 22
Candel Therapeutics Appoints Dr. Francesca Barone as Chief Scientific Officer
8:05am
8-K
EX-99.1
3fou7zav1dq3v56ve
12 Nov 21
Candel Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
8:11am
10-Q
u0pbh7ostej1iy4
8 Sep 21
Quarterly report
8:37am
8-K
EX-99.1
ppq y0yih3
8 Sep 21
Candel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Highlights
8:13am
8-K
EX-99.1
o4ie5h6ixkm8fva60
17 Aug 21
Other Events
4:41pm
8-K
EX-3.1
nkevfh
30 Jul 21
Departure of Directors or Certain Officers
12:00am
8-K
EX-3.2
vrwrd955
30 Jul 21
Departure of Directors or Certain Officers
12:00am
424B4
40zmz t5qfnp
28 Jul 21
Prospectus supplement with pricing info
4:02pm